Nasdaq
$3.78▲ 0.67%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $619.3MShares out 1.600M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
10- 9.25After-hours26.09.26 05:154Ownership#●●●
Annexon, Inc.
Douglas Love, an insider at Annexon, Inc., reported a change in beneficial ownership of securities as of September 24, 2026. This filing serves as a standard disclosure of executive share transactions and does not involve any material changes to the company's capital structure or listing status.…more
$3.78+0.67%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 8.12After-hours26.08.13 07:104Ownership
Annexon, Inc.
Annexon, Inc. insider Mark S. Blumenkranz reported changes in his beneficial ownership of securities effective August 10, 2026. This filing serves as the official Form 4 record detailing the insider's equity position adjustments.…more
$3.78+0.67%vs prev closeView filingShare - 8.12After-hours26.08.13 07:083Ownership
Annexon, Inc.
On August 7, 2026, Annexon, Inc. director Mark S. Blumenkranz granted a power of attorney to CEO Douglas Love and CFO Jennifer Lew to execute and file SEC Forms 3, 4, 5, and Form ID on his behalf. This action establishes a formal administrative process to ensure timely compliance with Section 16(a) of the Securities Exchange Act of 1934.…more
$3.78+0.67%vs prev closeView filingShare
9 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 10.16After-hours26.10.17 06:34#●●●#●●●
Annexon Biosciences Grants Stock Options to New Employees
Annexon Biosciences announced the grant of stock options for 1.27 million shares to six new non-executive employees. This is a standard equity inducement award for talent acquisition and has no immediate material impact on the stock.…more
$3.78+0.67%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 9.24Pre-market26.09.24 21:02
●●●●●●●● ●●●●● ●●●●●●
Annexon announced presentations regarding its geographic atrophy treatment candidate at the Retina Society meeting. The company expects to report Phase 3 clinical trial results in the fourth quarter of 2026.…more
$3.78+0.67%vs prev closeShareBenzinga - 9.16After-hours26.09.17 05:05
●●●●●●●● ●●●●● ●●●●●●
Annexon Biosciences has granted stock options for 275,500 shares to two new employees under Nasdaq listing rules. This is a routine compensation measure for talent acquisition and has no immediate impact on the company's valuation.…more
$3.78+0.67%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report